🧬 They are moving two blood-stage vaccine candidates, R78C and RH5.1, into Phase I/II trials.
🔬 This collaboration has resulted in five vaccine candidates since 2016, aiming to reduce malaria’s global impact.
💉 With growing cases, this initiative is vital for combatting malaria, especially among children.
Introduction:
The University of Oxford has announced an expansion of its collaborative efforts with ReciBioPharm in the realm of malaria vaccine development. This partnership is aimed at advancing two specific vaccine candidates, R78C and RH5.1, into Phase I/II clinical trials, building on a successful history of collaboration dating back to 2016.
- The University of Oxford and ReciBioPharm are expanding their collaboration to develop blood-stage malaria vaccine candidates for clinical trials.
- Since 2016, this partnership has successfully produced five malaria vaccine candidates.
- The manufacturing responsibilities for the R78C candidate have been transferred to ReciBioPharm, which is also set to undertake full production of RH5.1.
- Experts from both organizations emphasize the critical role of this collaboration in addressing the global malaria burden, which remains a major health challenge.
- According to the WHO, malaria results in significant morbidity and mortality, particularly in vulnerable populations such as young children in Africa.
Conclusion:
This enhanced collaboration between the University of Oxford and ReciBioPharm illustrates a strategic move towards accelerating the development and deployment of effective malaria vaccines. As highlighted by recent WHO reports, addressing the ongoing malaria epidemic necessitates innovative solutions, making these efforts vital for public health advancements in malaria-endemic regions. Future clinical trials will provide critical data on the efficacy and safety of the new vaccine candidates.
